Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Rheumatology Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Rheumatology Other
    NICE Issues Guidance on the Use of Febuxostat for Hyperuricaemia - (DGNews)
    Switching Aromatase Inhibitors in Breast Cancer Treatment Maintains Therapeutic Benefit for Patients With Joint Pain: Presented at SABCS - (DGDispatch)
    Adalimumab Decreases Rate of Anterior Uveitis in Ankylosing Spondylitis: Presented at AAO - (DGDispatch)
    Studies Examine Efficacy of Febuxostat in Gout, Protective Effects of Uric Acid - (DGNews)
    Adalimumab Does Not Inhibit Radiographic Progression in Ankylosing Spondylitis After 2 Years of Treatment: Presented at ACR-ARHP - (DGDispatch)

    News archive

     Recent webcasts/CME - Rheumatology Other
      B-Cell Biology and B-Cell-Targeted Therapies for Autoimmune Rheumatic Diseases: The Role of the Allied Health Professional
      Advances in B-Cell Biology in the Treatment of Autoimmune and Inflammatory Diseases
      Neuroinflammatory Diseases in Rheumatology
      Headache in Patients with Rheumatic Disease: When to Worry
      CNS Vasculitis

      Webcasts/CME archive

       Recent cases - Rheumatology Other
        Giant Cell Arteritis Complicated by Acute Pancreatitis: A Case Report
        Takayasu Arteritis in Children
        An Adolescent with Both Wegener's Granulomatosis and Chronic Blastomycosis
        Dysphagia Secondary to Dermatomyositis Treated Successfully with Intravenous Immunoglobulin: A Case Report
        F-18-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography for the Diagnosis of Takayasu's Arteritis in Stroke: A Case Report

        Cases archive
          




        my personal edition > rheumatology other > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Raloxifene, Estrogen Act Similarly On Postmenopausal Bone Tissue

        A DGReview of :"Bone Histomorphometric and Biochemical Marker Results of a 2-Year Placebo-Controlled Trial of Raloxifene in Postmenopausal Women"
        Journal of Bone and Mineral Research

        02/19/2002
        By Anne MacLennan


        Raloxifene has actions on bone tissue that are similar to those observed with estrogen.

        Further, the depressive effects of this selective estrogen receptor modulator on bone remodelling are less marked than are the effects observed with alendronate.

        These are the findings of a two-year placebo-controlled trial of raloxifene in postmenopausal women by Susan M Ott and colleagues from the Department of Medicine, University of Washington, Seattle, Washington, United States, the Department of Endocrinology, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands, and Eli Lilly and Company, Indianapolis, Indiana, United States.

        Raloxifene has earlier been shown to increase bone density. These authors sought to examine the effects of raloxifene on bone tissue by studying bone biopsy specimens before and after two years of raloxifene or placebo therapy.

        The women in this study were participants in the double-blind, placebo-controlled, multicentre Multiple Outcomes of Raloxifene Evaluation (MORE) trial. The women from two US and two European sites were included if they consented to a bone biopsy.

        Doctors did iliac crest bone biopsies at baseline and after two years, with tetracycline labeling preceding each biopsy. Overall, 65 paired biopsy specimens were evaluated with 25 patients on placebo, 22 patients on raloxifene HC1 (60 mg) and 18 on raloxifene HCl (120 mg) treatment.

        Researchers used standard histomorphometry to analyse the specimens. None of the biopsy specimens showed evidence of toxic effects on bone or bone cells or met criteria for osteomalacia.

        Biopsy specimens in the placebo and raloxifene groups had the appearance of normal bone, with no evidence of marrow fibrosis or increases in the amount of woven bone or numbers of empty osteocyte lacunae. Compared with the baseline, the bone formation rate (BFR) decreased significantly in both groups on raloxifene treatment.

        The change in BFR in the group treated with 120 mg of raloxifene was -62.3 percent, which was significantly lower than the change in the placebo group of -21.0 percent.

        No change in resorption parameters could be measured by histomorphometry, but there was a decrease in urinary type I collagen excretion.

        These results suggest raloxifene's actions on bone tissue are similar to those observed with estrogen; the depressive effects on bone remodelling are less marked than are the effects seen with alendronate, these authors conclude.
        J Bone Miner Res 2002;17:341-348. "Bone Histomorphometric and Biochemical Marker Results of a 2-Year Placebo-Controlled Trial of Raloxifene in Postmenopausal Women"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send